Evidence map›Paper›PMID 41311914›Full record

ArticleOpen forum infectious diseases2025

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and

Sujata M Bhavnani, Jeffrey P Hammel, Nikolas J Onufrak, Jason M Pogue, Ronald N Jones, Helio S Sader, George L Drusano, John S Bradley, David R Andes, William A Craig and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sujata M BhavnaniInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Jeffrey P HammelInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Nikolas J OnufrakInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Jason M PogueDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-4780-6215
Ronald N JonesJMI Laboratories/Element, North Liberty, Iowa, USA.
Helio S SaderJMI Laboratories/Element, North Liberty, Iowa, USA.
George L DrusanoInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.
John S BradleyUniversity of California at San Diego, San Diego, California, USA.
David R AndesDepartments of Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
William A CraigDepartment of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
Paul G AmbroseInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.

Funding

Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select AgenR01AI090802 · NIAID · UNIVERSITY OF FLORIDA · PI DRUSANO, GEORGE LOUIS, LOUIE, ARNOLD · 2010 to 2014
$4.0M
NIAID NIH HHS R01 AI090802
6 · The paper itself

Abstract

Background: Appropriate in vitro susceptibility testing interpretive criteria (STIC) are crucial to ensure optimal patient care. Pharmacometric analyses for aminoglycosides were undertaken to provide recommendations for dosing regimens adjusted for renal function and to support the original 2019 and 2023 reassessments of STIC for Enterobacterales and Methods: Using simulation, traditional and extended-interval aminoglycoside dosing regimens adjusted for renal function that match drug exposures for patients with normal renal function were constructed. Using in vitro surveillance, nonclinical pharmacokinetic-pharmacodynamic (PK-PD), population pharmacokinetic (PK) model data, and simulation, PK-PD target attainment analyses were carried out to assess aminoglycoside STIC for Enterobacterales and Results: Aminoglycoside dosing regimens adjusted for renal function were successfully identified. For Enterobacterales and Conclusions: Use of dosing recommendations adjusted for renal function and United States Committee on Antimicrobial Susceptibility Testing-recommended STIC will allow clinicians to optimally use aminoglycosides.

Indexed as

aminoglycosidesin vitro susceptibility test interpretive criteriasusceptibility breakpoints

Identifiers

PMID41311914
PMCPMC12651555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.